HC Wainwright Has Pessimistic Outlook of ANRO Q3 Earnings

Key Points

• HC Wainwright has lowered its earnings forecasts for Alto Neuroscience, now expecting a Q3 2025 EPS of ($0.74), down from ($0.71), while maintaining a "Buy" rating with a target price of $10.00.
• The company reported a loss per share of ($0.65) in its last quarterly earnings, missing the consensus estimate of ($0.57) by ($0.08).
• Market analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average target price of $8.50, while Wedbush has issued a "neutral" rating with a $4.00 target price.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 earnings estimates for shares of Alto Neuroscience in a research note issued to investors on Monday, August 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.74) for the quarter, down from their previous forecast of ($0.71). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($2.69) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($3.26) EPS, FY2027 earnings at ($3.23) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($1.77) EPS.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08).

Separately, Wedbush reissued a "neutral" rating and set a $4.00 price target on shares of Alto Neuroscience in a research report on Thursday, May 15th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Alto Neuroscience currently has an average rating of "Moderate Buy" and an average target price of $8.50.

Alto Neuroscience Stock Performance

ANRO traded up $0.0750 during trading on Wednesday, reaching $3.9750. 73,161 shares of the company's stock were exchanged, compared to its average volume of 259,045. Alto Neuroscience has a 1 year low of $1.60 and a 1 year high of $15.04. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The stock has a market capitalization of $107.63 million, a P/E ratio of -1.66 and a beta of 1.84. The company's fifty day simple moving average is $2.80 and its 200-day simple moving average is $2.70.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can purchased a new position in shares of Alto Neuroscience during the 2nd quarter valued at approximately $25,000. Ground Swell Capital LLC purchased a new position in shares of Alto Neuroscience during the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Alto Neuroscience during the 2nd quarter valued at approximately $33,000. AlphaCore Capital LLC increased its holdings in shares of Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock valued at $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Alto Neuroscience by 40.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after purchasing an additional 3,139 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.